Selected research
Market Structure
Global Life Science CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Life Science CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Life Science CDMO include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Life Science CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Life Science CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Life Science CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Life Science CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.
Life Science CDMO Segment by Company
Lonza Group
Thermo Fisher Scientific
Catalent
WuXi Biologics
Samsung Biologics
Siegfried
Fujifilm Diosynth Biotechnologies
Lars Petersen
Recipharm
Boehringer Ingelheim
MilliporeSigma
Aenova Group
AGC Parma Chemicals
GenScript
Novartis
Sai Life Sciences
Life Science CDMO Segment by Type
Active Pharmaceutical Ingredient (API) CDMO
Biologics CDMO
Finished Dosage Form (FDF) CDMO
Others
Life Science CDMO Segment by Application
Pharmaceutical
Clinical
Research
Life Science CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Life Science CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Life Science CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Life Science CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Life Science CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Life Science CDMO industry.
Chapter 3: Detailed analysis of Life Science CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Life Science CDMOrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Active Pharmaceutical Ingredient (API) CDMO
- Biologics CDMO
- Finished Dosage Form (FDF) CDMO
- Others
Applications
- Pharmaceutical
- Clinical
- Research
Companies covered
- Lonza Group
- Thermo Fisher Scientific
- Catalent
- WuXi Biologics
- Samsung Biologics
- Siegfried
- Fujifilm Diosynth Biotechnologies
- Lars Petersen
- Recipharm
- Boehringer Ingelheim
- MilliporeSigma
- Aenova Group
- AGC Parma Chemicals
- GenScript
- Novartis
- Sai Life Sciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Life Science CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Active Pharmaceutical Ingredient (API) CDMO
- 1.2.3 Biologics CDMO
- 1.2.4 Finished Dosage Form (FDF) CDMO
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Life Science CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Pharmaceutical
- 1.3.3 Clinical
- 1.3.4 Research
- 1.4 Global Market Growth Prospects
- 1.5 Global Life Science CDMO Growth Trends by Region
- 1.5.1 Global Life Science CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Life Science CDMO Market Size by Region (2021-2026)
- 1.5.3 Life Science CDMO Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Life Science CDMO Market Dynamics
- 2.1 Life Science CDMO Industry Trends
- 2.2 Life Science CDMO Industry Drivers
- 2.3 Life Science CDMO Industry Opportunities and Challenges
- 2.4 Life Science CDMO Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Life Science CDMO Revenue by Company (2021-2026)
- 3.2 Global Life Science CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Life Science CDMO Key Company Head office and Area Served
- 3.4 Global Life Science CDMO Company, Product Type & Application
- 3.5 Global Life Science CDMO Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Life Science CDMO Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Life Science CDMO Players Market Share by Revenue in 2025
- 3.6.3 2025 Life Science CDMO Tier 1, Tier 2, and Tier 3
4 Life Science CDMO Market by Type
- 4.1 Global Life Science CDMO Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Life Science CDMO Market Size by Type (2021-2032)
- 4.3 Global Life Science CDMO Market Size Share by Type (2021-2032)
5 Life Science CDMO Market by Application
- 5.1 Global Life Science CDMO Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Life Science CDMO Market Size by Application (2021-2032)
- 5.3 Global Life Science CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Lonza Group
- 6.1.1 Lonza Group Company Information
- 6.1.2 Lonza Group Business Overview
- 6.1.3 Lonza Group Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Lonza Group Life Science CDMO Product Portfolio
- 6.1.5 Lonza Group Recent Developments
- 6.2 Thermo Fisher Scientific
- 6.2.1 Thermo Fisher Scientific Company Information
- 6.2.2 Thermo Fisher Scientific Business Overview
- 6.2.3 Thermo Fisher Scientific Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Thermo Fisher Scientific Life Science CDMO Product Portfolio
- 6.2.5 Thermo Fisher Scientific Recent Developments
- 6.3 Catalent
- 6.3.1 Catalent Company Information
- 6.3.2 Catalent Business Overview
- 6.3.3 Catalent Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Catalent Life Science CDMO Product Portfolio
- 6.3.5 Catalent Recent Developments
- 6.4 WuXi Biologics
- 6.4.1 WuXi Biologics Company Information
- 6.4.2 WuXi Biologics Business Overview
- 6.4.3 WuXi Biologics Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 WuXi Biologics Life Science CDMO Product Portfolio
- 6.4.5 WuXi Biologics Recent Developments
- 6.5 Samsung Biologics
- 6.5.1 Samsung Biologics Company Information
- 6.5.2 Samsung Biologics Business Overview
- 6.5.3 Samsung Biologics Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Samsung Biologics Life Science CDMO Product Portfolio
- 6.5.5 Samsung Biologics Recent Developments
- 6.6 Siegfried
- 6.6.1 Siegfried Company Information
- 6.6.2 Siegfried Business Overview
- 6.6.3 Siegfried Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Siegfried Life Science CDMO Product Portfolio
- 6.6.5 Siegfried Recent Developments
- 6.7 Fujifilm Diosynth Biotechnologies
- 6.7.1 Fujifilm Diosynth Biotechnologies Company Information
- 6.7.2 Fujifilm Diosynth Biotechnologies Business Overview
- 6.7.3 Fujifilm Diosynth Biotechnologies Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio
- 6.7.5 Fujifilm Diosynth Biotechnologies Recent Developments
- 6.8 Lars Petersen
- 6.8.1 Lars Petersen Company Information
- 6.8.2 Lars Petersen Business Overview
- 6.8.3 Lars Petersen Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Lars Petersen Life Science CDMO Product Portfolio
- 6.8.5 Lars Petersen Recent Developments
- 6.9 Recipharm
- 6.9.1 Recipharm Company Information
- 6.9.2 Recipharm Business Overview
- 6.9.3 Recipharm Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Recipharm Life Science CDMO Product Portfolio
- 6.9.5 Recipharm Recent Developments
- 6.10 Boehringer Ingelheim
- 6.10.1 Boehringer Ingelheim Company Information
- 6.10.2 Boehringer Ingelheim Business Overview
- 6.10.3 Boehringer Ingelheim Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Boehringer Ingelheim Life Science CDMO Product Portfolio
- 6.10.5 Boehringer Ingelheim Recent Developments
- 6.11 MilliporeSigma
- 6.11.1 MilliporeSigma Company Information
- 6.11.2 MilliporeSigma Business Overview
- 6.11.3 MilliporeSigma Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 MilliporeSigma Life Science CDMO Product Portfolio
- 6.11.5 MilliporeSigma Recent Developments
- 6.12 Aenova Group
- 6.12.1 Aenova Group Company Information
- 6.12.2 Aenova Group Business Overview
- 6.12.3 Aenova Group Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Aenova Group Life Science CDMO Product Portfolio
- 6.12.5 Aenova Group Recent Developments
- 6.13 AGC Parma Chemicals
- 6.13.1 AGC Parma Chemicals Company Information
- 6.13.2 AGC Parma Chemicals Business Overview
- 6.13.3 AGC Parma Chemicals Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 AGC Parma Chemicals Life Science CDMO Product Portfolio
- 6.13.5 AGC Parma Chemicals Recent Developments
- 6.14 GenScript
- 6.14.1 GenScript Company Information
- 6.14.2 GenScript Business Overview
- 6.14.3 GenScript Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 GenScript Life Science CDMO Product Portfolio
- 6.14.5 GenScript Recent Developments
- 6.15 Novartis
- 6.15.1 Novartis Company Information
- 6.15.2 Novartis Business Overview
- 6.15.3 Novartis Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Novartis Life Science CDMO Product Portfolio
- 6.15.5 Novartis Recent Developments
- 6.16 Sai Life Sciences
- 6.16.1 Sai Life Sciences Company Information
- 6.16.2 Sai Life Sciences Business Overview
- 6.16.3 Sai Life Sciences Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Sai Life Sciences Life Science CDMO Product Portfolio
- 6.16.5 Sai Life Sciences Recent Developments
7 North America
- 7.1 North America Life Science CDMO Market Size (2021-2032)
- 7.2 North America Life Science CDMO Market Size by Type
- 7.2.1 North America Life Science CDMO Market Size by Type (2021-2026)
- 7.2.2 North America Life Science CDMO Market Size by Type (2027-2032)
- 7.2.3 North America Life Science CDMO Market Share by Type (2021-2032)
- 7.3 North America Life Science CDMO Market Size by Application
- 7.3.1 North America Life Science CDMO Market Size by Application (2021-2026)
- 7.3.2 North America Life Science CDMO Market Size by Application (2027-2032)
- 7.3.3 North America Life Science CDMO Market Share by Application (2021-2032)
- 7.4 North America Life Science CDMO Market Size by Country
- 7.4.1 North America Life Science CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Life Science CDMO Market Size by Country (2021-2026)
- 7.4.3 North America Life Science CDMO Market Size by Country (2027-2032)
- 7.4.4 North America Life Science CDMO Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Life Science CDMO Market Size (2021-2032)
- 8.2 Europe Life Science CDMO Market Size by Type
- 8.2.1 Europe Life Science CDMO Market Size by Type (2021-2026)
- 8.2.2 Europe Life Science CDMO Market Size by Type (2027-2032)
- 8.2.3 Europe Life Science CDMO Market Share by Type (2021-2032)
- 8.3 Europe Life Science CDMO Market Size by Application
- 8.3.1 Europe Life Science CDMO Market Size by Application (2021-2026)
- 8.3.2 Europe Life Science CDMO Market Size by Application (2027-2032)
- 8.3.3 Europe Life Science CDMO Market Share by Application (2021-2032)
- 8.4 Europe Life Science CDMO Market Size by Country
- 8.4.1 Europe Life Science CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Life Science CDMO Market Size by Country (2021-2026)
- 8.4.3 Europe Life Science CDMO Market Size by Country (2027-2032)
- 8.4.4 Europe Life Science CDMO Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Life Science CDMO Market Size (2021-2032)
- 9.2 China Life Science CDMO Market Size by Type
- 9.2.1 China Life Science CDMO Market Size by Type (2021-2026)
- 9.2.2 China Life Science CDMO Market Size by Type (2027-2032)
- 9.2.3 China Life Science CDMO Market Share by Type (2021-2032)
- 9.3 China Life Science CDMO Market Size by Application
- 9.3.1 China Life Science CDMO Market Size by Application (2021-2026)
- 9.3.2 China Life Science CDMO Market Size by Application (2027-2032)
- 9.3.3 China Life Science CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Life Science CDMO Market Size (2021-2032)
- 10.2 Asia Life Science CDMO Market Size by Type
- 10.2.1 Asia Life Science CDMO Market Size by Type (2021-2026)
- 10.2.2 Asia Life Science CDMO Market Size by Type (2027-2032)
- 10.2.3 Asia Life Science CDMO Market Share by Type (2021-2032)
- 10.3 Asia Life Science CDMO Market Size by Application
- 10.3.1 Asia Life Science CDMO Market Size by Application (2021-2026)
- 10.3.2 Asia Life Science CDMO Market Size by Application (2027-2032)
- 10.3.3 Asia Life Science CDMO Market Share by Application (2021-2032)
- 10.4 Asia Life Science CDMO Market Size by Country
- 10.4.1 Asia Life Science CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Life Science CDMO Market Size by Country (2021-2026)
- 10.4.3 Asia Life Science CDMO Market Size by Country (2027-2032)
- 10.4.4 Asia Life Science CDMO Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Life Science CDMO Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Life Science CDMO Market Size by Type
- 11.2.1 South America, Middle East & Africa Life Science CDMO Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Life Science CDMO Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Life Science CDMO Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Life Science CDMO Market Size by Application
- 11.3.1 South America, Middle East & Africa Life Science CDMO Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Life Science CDMO Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Life Science CDMO Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Life Science CDMO Market Size by Country
- 11.4.1 South America, Middle East & Africa Life Science CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Life Science CDMO Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Life Science CDMO Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Life Science CDMO Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst